ABVX vs TLX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TLX Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Telix Pharmaceuticals Limited American Depositary Shares (TLX) driven by superior Valuation, Growth & Margin, Momentum & Technical while ABVX counters with relative strength in Options & Structure. Fundamentally, ABVX trades at N/M Forward P/E with -6270.4% operating margin (-6.8% YoY revenue) versus TLX at N/M Forward P/E and 6.2% operating margin (+22.3% YoY). In options structure, ABVX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against TLX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABVX | TLX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.9B | $3.2B | Larger Scale | ABVX |
| Trailing P/E Ratio Valuation | N/M | 93.6x | Lower Multiple | TLX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -6.8% | +22.3% | Higher Growth | TLX |
| Operating Margin (TTM) Profitability | -6270.4% | 6.2% | Higher Margin | TLX |
| Net Profit Margin Profitability | 0.0% | 3.8% | Higher Margin | TLX |
| Return on Equity (ROE) Capital Efficiency | -252.3% | 7.4% | Higher ROE | TLX |
| 52-Week Range Position Momentum | 17% ($70โ$149) | 39% ($6โ$13) | Stronger Trend | TLX |
| Beta / 30D Volatility Risk Regime | 1.38ฮฒ ยท 48% Vol | 0.84ฮฒ ยท 62% Vol | Lower Realized Risk | ABVX |
| Unified Institutional Score Composite Signal | 55.6 / 100 (HOLD) | 46.4 / 100 (HOLD) | Higher Composite | ABVX |